| Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1 G Levkowitz, H Waterman, SA Ettenberg, M Katz, AY Tsygankov, I Alroy, ... Molecular cell 4 (6), 1029-1040, 1999 | 1263 | 1999 |
| Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer KJ Chavez, SV Garimella, S Lipkowitz Breast disease 32 (1-2), 35-48, 2011 | 1053 | 2011 |
| Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b K Bachmaier, C Krawczyk, I Kozieradzki, YY Kong, T Sasaki, ... Nature 403 (6766), 211-216, 2000 | 815 | 2000 |
| Chemotherapy augments TRAIL-induced apoptosis in breast cell lines MM Keane, SA Ettenberg, MM Nau, EK Russell, S Lipkowitz Cancer research 59 (3), 734-741, 1999 | 759 | 1999 |
| Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian … M Cuello, SA Ettenberg, AS Clark, MM Keane, RH Posner, MM Nau, ... Cancer research 61 (12), 4892-4900, 2001 | 507 | 2001 |
| RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis S Lipkowitz, AM Weissman Nature reviews Cancer 11 (9), 629-643, 2011 | 450 | 2011 |
| Fas expression and function in normal and malignant breast cell lines MM Keane, SA Ettenberg, GA Lowrey, EK Russell, S Lipkowitz Cancer research 56 (20), 4791-4798, 1996 | 317 | 1996 |
| The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IκB kinase and c-Jun N-terminal kinase Y Lin, A Devin, AMY Cook, MM Keane, M Kelliher, S Lipkowitz, Z Liu Molecular and cellular biology 20 (18), 6638-6645, 2000 | 302 | 2000 |
| Safety and clinical activity of the programmed Death-Ligand 1 inhibitor Durvalumab in combination with poly (ADP-ribose) polymerase inhibitor olaparib or vascular endothelial … JM Lee, A Cimino-Mathews, CJ Peer, A Zimmer, S Lipkowitz, ... Journal of Clinical Oncology 35 (19), 2193-2202, 2017 | 256 | 2017 |
| Cloning and characterization of cbl-b: a SH3 binding protein with homology to the c-cbl proto-oncogene. MM Keane, OM Rivero-Lezcano, JA Mitchell, KC Robbins, S Lipkowitz Oncogene 10 (12), 2367-2377, 1995 | 256 | 1995 |
| Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells M Cuello, SA Ettenberg, MM Nau, S Lipkowitz Gynecologic oncology 81 (3), 380-390, 2001 | 246 | 2001 |
| Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme L Rahman, D Voeller, M Rahman, S Lipkowitz, C Allegra, JC Barrett, ... Cancer cell 5 (4), 341-351, 2004 | 238 | 2004 |
| New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer SX Yang, E Polley, S Lipkowitz Cancer treatment reviews 45, 87-96, 2016 | 235 | 2016 |
| TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype M Rahman, SR Davis, JG Pumphrey, J Bao, MM Nau, PS Meltzer, ... Breast cancer research and treatment 113, 217-230, 2009 | 215 | 2009 |
| Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine … AR Tan, X Yang, SM Hewitt, A Berman, ER Lepper, A Sparreboom, ... Journal of Clinical Oncology 22 (15), 3080-3090, 2004 | 213 | 2004 |
| WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation A Magnifico, S Ettenberg, C Yang, J Mariano, S Tiwari, S Fang, ... Journal of Biological Chemistry 278 (44), 43169-43177, 2003 | 211 | 2003 |
| Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study JM Lee, J Nair, A Zimmer, S Lipkowitz, CM Annunziata, MJ Merino, ... The Lancet Oncology 19 (2), 207-215, 2018 | 203 | 2018 |
| Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex SA Ettenberg, A Magnifico, M Cuello, MM Nau, YR Rubinstein, Y Yarden, ... Journal of Biological Chemistry 276 (29), 27677-27684, 2001 | 196 | 2001 |
| Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase II study EJ Lampert, A Zimmer, M Padget, A Cimino-Mathews, JR Nair, Y Liu, ... Clinical Cancer Research 26 (16), 4268-4279, 2020 | 182 | 2020 |
| Cutting edge: regulation of T cell activation threshold by CD28 costimulation through targeting Cbl-b for ubiquitination J Zhang, T Bárdos, D Li, I Gál, C Vermes, J Xu, K Mikecz, A Finnegan, ... The Journal of Immunology 169 (5), 2236-2240, 2002 | 181 | 2002 |
Christina AnnunziataSenior Vice President, American Cancer SocietyПідтверджена електронна адреса в cancer.org
